JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boehm, J. E.
Right arrow Articles by Lewis, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boehm, J. E.
Right arrow Articles by Lewis, R. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 40, 28632-28636, October 1, 1999


Rac-dependent Anti-apoptotic Signaling by the Insulin Receptor Cytoplasmic Domain*

Jason E. BoehmDagger §, Oleg V. ChaikaDagger , and Robert E. LewisDagger parallel **

From the Dagger  Eppley Institute for Research in Cancer and Allied Diseases,  Department of Biochemistry and Molecular Biology, and parallel  Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198-6805

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Mutations in the cytoplasmic domain of the insulin receptor that block the ability of the receptor to stimulate glucose uptake do not block the receptor's ability to inhibit apoptosis (Boehm, J. E., Chaika, O. V., and Lewis, R. E. (1998) J. Biol. Chem. 273, 7169-7176). To characterize this survival pathway we used a chimeric receptor (CSF1R/IR) consisting of the ligand-binding domain of the colony-stimulating factor-1 receptor spliced to the cytoplasmic domain of the insulin receptor and a mutated version of the chimeric receptor containing a 12-amino acid deletion of the juxtamembrane domain (CSF1R/IRDelta 960). In addition to the inhibition of apoptosis, activation of either the CSF1R/IR or the CSF1R/IRDelta 960 rapidly induced membrane ruffling in Rat1 fibroblasts. The small GTPase Rac mediates membrane ruffling. Activated and dominant-inhibitory mutants of Rac and other small GTPases were expressed in Rat1 fibroblasts to examine a potential link between the intracellular pathways that induce membrane ruffling and promote cell survival. The anti-apoptotic action of the CSF1R/IRDelta 960 was reversed by dominant-inhibitory RacN17, but not by RasN17 or Cdc42N17. Activated RacV12, but not RasD12 or Cdc42V12, promoted cell survival in the absence of insulin. These data implicate Rac as a mediator of an unique anti-apoptotic signaling pathway activated by the insulin receptor cytoplasmic domain.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The cellular receptor for insulin controls diverse intracellular pathways that regulate metabolism, growth, and development. One conventional approach for identifying the molecular components that constitute these different pathways has been the selective mutagenesis of the receptor's cytoplasmic domain in an effort to discretely dissociate one biological action of insulin from another (1-7). These observations have led to the suggestion that different regions of the insulin receptor cytoplasmic domain play distinct roles in modulating the biological effects of insulin.

The insulin and IGF I1 receptors are potent inhibitors of apoptosis (6, 8, 9). Recent studies with a CSF1R/IR suggest that the insulin receptor cytoplasmic domain activates intracellular signaling pathways that are independent of its ability to phosphorylate IRS proteins and Shc (5, 6). The mutated CSF1R/IRDelta 960 lacks the ability to phosphorylate the receptor substrates IRS-1 and Shc. Coincident with the loss of receptor substrate phosphorylation, the Delta 960 deletion also blocks the activation of ERK MAP kinases, the activation of PI 3-kinase associated with IRS-1, and the stimulation of glucose transport. However, the Delta 960 deletion does not prevent the receptor from inhibiting apoptosis (6).

Previous studies of anti-apoptotic signaling by growth factor receptors have identified PI 3-kinase and the serine/threonine kinase Akt as part of the mechanism that promotes cell survival (10-13). The insulin and IGF I receptors activate PI 3-kinase and, subsequently, Akt through their ability to phosphorylate IRS proteins at sites that facilitate interaction of these receptor substrates with the noncatalytic subunit of PI 3-kinase, p85 (14-16). These observations suggested that alternative pathways could contribute to the insulin receptor's anti-apoptotic activity.

To identify additional mediators of anti-apoptotic signaling activated by the insulin receptor cytoplasmic domain, other biological effects of the CSF1R/IRDelta 960 were investigated. We observed that the CSF1R/IRDelta 960 rapidly induced membrane ruffling in a manner dependent on the small GTPase Rac. A contribution of Rac to anti-apoptotic signaling by the chimeric receptor was indicated by the observation that dominant-negative RacN17 blocked survival signals from the CSF1R/IRDelta 960. Furthermore, activated RacV12, but not activated RasD12 or Cdc42V12, was sufficient to promote survival in the absence of growth factor stimulation. These results implicate Rac as a mediator of an additional anti-apoptotic signaling pathway activated by the insulin receptor cytoplasmic domain in a manner independent of IRS phosphorylation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Plasmids and Constructs-- cDNAs encoding Myc-tagged RacV12, RacN17, Cdc42V12, Cdc42N17, Ha-RasD12, and Ha-RasN17 were gifts from A. Hall (London). Each cDNA was cloned into the EcoRI site of the retroviral vector pSRalpha . Recombinant retroviruses were made by transfection into a packaging cell line (17). cDNAs encoding RacV12 and RacN17 containing a T7 epitope tag were gifts of D. Bar-Sagi (Stony Brook, NY). The CSF1R/IR and CSF1R/IRDelta 960 were constructed previously (5).

Cell Lines-- Rat1 mycER fibroblasts (18) (G. Evan, London) were transfected with the CSF1R/IR or the CSF1R/IRDelta 960 with LipofectAMINE (Life Technologies, Inc.). Stable lines expressing each chimeric receptor were isolated as described previously (5) by selection with G418 followed by fluorescence-activated cell sorting using an antibody to the ligand binding domain of the human CSF-1 receptor. For the expression of activated and dominant-negative forms of Rac, Ras, and Cdc42, Rat1 mycER cells were infected at a multiplicity of infection of at least 5 with ecotropic retroviruses encoding each Myc-tagged cDNA and selected with G418 (400 µg/ml).

Analysis of Akt-- Cells expressing the CSF1R/IR or the CSF1R/IRDelta 960 (5 × 105/35-mm dish) were treated with or without 10 nM CSF-1 or 100 nM insulin for 10 min, lysed, and the phosphorylation state of Akt was determined by Western blot with PhosphoPlus Akt (Ser473) antibodies (New England Biolabs). Akt kinase activity was determined as described previously (19) by the phosphorylation of histone H2B in immunoprecipitates of Akt from treated and untreated cells.

Microinjection and Immunofluorescence-- Rat1mycER (5 × 104) cells expressing the CSF1R/IR or the CSF1R/IRDelta 960 were plated onto gridded glass coverslips (Bellco), incubated in serum-free Dulbecco's modified Eagle's medium for 24 h, and injected as described previously for REF-52 fibroblasts (20) with 50 ng/µl pCGT T7-tagged RacV12 or RacN17 using an Eppendorf automated microinjection system. The expression of RacV12 and RacN17 were detected with mouse anti-T7 antibodies (1:700, Novagen) and FITC-conjugated goat anti-mouse antibodies (1:100, Southern Biotechnology Associates) in cells fixed with 2.5% paraformaldehyde and permeablized with 0.1% Triton X-100. Membrane ruffles were detected in fixed and permeablized cells with 0.01 µg/ml TRITC-phalloidin.

Quantification of Apoptosis-- Apoptosis in cells stably expressing activated or dominant-negative forms of Ras, Rac 1, or Cdc42 was determined by time-lapse video microscopy (8) and by determining the number of apoptotic cells on a specific grid at 0, 10, and 20 h posttreatment. Fields of at least 300 cells were used to quantify apoptosis.

Apoptosis in cells microinjected with RacN17 was determined by co-injection with 20 ng/µl pEFGFP. Cells were treated with 100 nM tamoxifen, 10 nM CSF-1, or 1 µM insulin as indicated, and cells expressing GFP were observed every 2 h for a total of 20 h. The amount of apoptosis among injected cells was quantified. Cell death caused by microinjection was determined by the injection of pEFGFP alone and subtracted from the amount of death induced by each experimental condition. Microinjected cells expressing GFP were evaluated within the microscopic field for each condition. Each condition was repeated at least five times.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Previous studies have shown that mutations in the CSF1R/IR can dissociate its ability to phosphorylate important intracellular substrates from certain receptor-stimulated biological effects (5, 6). A 12-amino acid deletion (Delta 960) blocks the ability of the CSF1R/IR to phosphorylate IRS-1 and Shc, activate the MAP kinases ERK1 and ERK2, activate PI 3-kinase associated with IRS-1, and stimulate glucose transport (5, 6). Despite the uncoupling of these intracellular effectors from the receptor, the CSF1R/IRDelta 960 still retains its ability to stimulate adipocyte differentiation (5) and protect cells against apoptosis (6). However, inhibition of apoptosis and induction of differentiation are assayed over much longer periods of time (hours to days) than the amount of time (minutes) required to detect biological events that are inhibited by the Delta 960 mutation. This fact prevented us from excluding the possibility that small amounts of IRS or Shc phosphorylation could result from prolonged activation of the CSF1R/IRDelta 960 to inhibit apoptosis or stimulate differentiation. We, therefore, looked for biological effects of insulin that could be mimicked by activation of the CSF1R/IR and occurred over the same rapid time course as the phosphorylation of insulin receptor substrates and the stimulation of glucose uptake.

Insulin and insulin-like growth factors rapidly induce membrane ruffling (lamellipodia) in cells (21, 22). To investigate the effect of the Delta 960 deletion on the ability of the chimeric receptor to stimulate membrane ruffling, Rat1mycER fibroblasts stably expressing the CSF1R/IR, the CSF1R/IRDelta 960, or transfected with the expression vector alone were treated with or without 10 nM CSF-1 or 100 nM insulin for 2 min. The cells were fixed immediately, and polymerized actin was detected with TRITC-labeled phalloidin. Fluorescence microscopy revealed that CSF-1 and insulin rapidly induced lamellipodia in cells expressing either the CSF1R/IR or CSF1R/IRDelta 960 (Fig. 1). However, in control cells only insulin was able to induce membrane ruffling (Fig. 1). The ability of the CSF1R/IRDelta 960 to rapidly stimulate membrane ruffling suggested that the induction of this cytoskeletal rearrangement was not dependent upon IRS and Shc phosphorylation. Lamellipodia formation is dependent upon the activation of the small GTPase Rac (23). To investigate the role of Rac in lamellipodia formation by the CSF1R/IRDelta 960, dominant-inhibitory RacN17 was microinjected into Rat1mycER fibroblasts expressing the CSF1R/IRDelta 960, and the cells were treated with CSF-1. Expression of RacN17 blocked the ability of CSF-1 to induce membrane ruffling in microinjected cells, but not in adjacent, uninjected cells (data not shown).


View larger version (147K):
[in this window]
[in a new window]
 
Fig. 1.   Membrane ruffling in cells expressing the CSF1R/IR or the CSF1R/IRDelta 960. Rat1mycER cells stably transfected with the expression vector alone, or expressing the CSF1R/IR or the CSF1R/IRDelta 960 were incubated in serum-free media for 48 h, treated with or without 100 nM insulin or 10 nM CSF-1 for 2 min, and fixed immediately with 2.5% paraformaldehyde. Actin microfilaments were detected with TRITC-phalloidin. Lamellipodia are indicated by the white arrows.

We observed previously that the Delta 960 mutation blocks the ability of the CSF1R/IR to stimulate PI 3-kinase activity associated with tyrosine phosphorylated proteins, including IRS-1 (6). Phosphorylation of the 3' position of PI is thought to be a key event in the activation of guanine nucleotide exchange factors for Rac (24, 25). Binding of PI(3,4,5)P3 to the pleckstrin homology domain of Akt is also critical to the activation of the serine/threonine kinase (26-29). To confirm that the CSF1R/IRDelta 960 was not activating known PI 3-kinase signaling pathways, the ability of cells expressing the CSF1R/IR or the CSF1R/IRDelta 960 to activate Akt was examined. Insulin (100 nM) stimulated the phosphorylation of Akt in cells expressing the CSF1R/IR or the CSF1R/IRDelta 960, as determined by Western blotting with an antibody specific for Akt phosphorylated on Ser473. However, only cells expressing the intact CSF1R/IR were able to stimulate phosphorylation in response to CSF-1 treatment (Fig. 2A). The level of Akt expressed in each treatment group was similar, suggesting that the Delta 960 mutation was responsible for the inability of CSF-1 to stimulate Akt phosphorylation in cells expressing the chimeric receptor (Fig. 2B). Similar results were obtained when the kinase activity of Akt was analyzed. CSF-1 stimulated the kinase activity of Akt immunoprecipitated from cells expressing the intact CSF1R/IR but not from cells expressing the CSF1R/IRDelta 960 (Fig. 2C). These data indicate the activation of Akt by the insulin receptor kinase is dependent upon IRS-associated PI 3-kinase activity but that the rapid, Rac-dependent induction of lamellipodia by the CSF1R/IRDelta 960 is independent of the activation of PI 3-kinase. Alternatively, a second, distinct PI 3-kinase pathway may also be stimulated independent of IRS proteins by the insulin receptor kinase to activate Rac.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 2.   Phosphorylation and activation of Akt in cells expressing the CSF1R/IR or CSF1R/IRDelta 960. Rat1mycER cells expressing the CSF1R/IR or the CSF1R/IRDelta 960 were left untreated or treated with 10 nM CSF-1 or 100 nM insulin for 10 min at 37 °C. A, activated Akt was immunoprecipitated from the cell lysates using phospho-specific Akt antibodies, separated by electrophoresis, and blotted to nitrocellulose. Activated Akt was detected by probing the blots with the phospho-specific Akt antibodies. B, the Akt expression in the samples from A was determined by immunoprecipitation and probing a portion of the cell lysate with antibodies to Akt. C, the activation of Akt was determined by examining the phosphorylation of histone H2B by Akt immunoprecipitated from cells expressing the CSF1R/IR or the CSF1R/IRDelta 960. Cells were treated with CSF-1 or insulin as indicated. D, the Akt expression in the samples from C was determined by immunoprecipitating and probing a portion of the cell lysate with antibodies to Akt.

PI 3-kinase and Akt are known mediators of growth factor-stimulated anti-apoptotic signaling pathways (10-13). CSF-1 inhibited apoptosis (6) and stimulated Rac-dependent membrane ruffling (Fig. 1), but was unable to activate PI 3-kinase (6) or Akt (Fig. 2) in cells expressing the CSF1R/IRDelta 960. These observations raise the possibility that Rac mediates anti-apoptotic signaling by the insulin receptor cytoplasmic domain. To test the role of Rac in anti-apoptotic signaling by insulin, constitutively active or dominant-inhibitory forms of small GTPases were stably expressed in Rat1mycER fibroblasts and tested for their ability to inhibit apoptosis. Rat1mycER cells alone or expressing the different small GTPases were treated with 100 nM tamoxifen to induce apoptosis (18) and with or without 1 µM insulin for 20 h. Cells expressing RacV12 and treated with 100 nM tamoxifen showed a significantly reduced level of apoptosis when compared with control Rat1mycER cells treated with tamoxifen (Fig. 3A). Furthermore, insulin treatment did not enhance the survival of tamoxifen-treated cells expressing RacV12. The protective role of RacV12 in tamoxifen-treated Rat1mycER fibroblasts was further demonstrated by time-lapse video microscopy (Fig. 3B). In contrast, the expression of activated Cdc42V12 showed no ability to protect cells from tamoxifen-induced apoptosis and had no effect on insulin's anti-apoptotic activity, suggesting that Cdc42 is not involved in an insulin-mediated survival pathway (Fig. 3A). Activated RasD12 also had no protective effect against tamoxifen-induced apoptosis, but instead inhibited the anti-apoptotic activities of insulin. The actions of activated RasD12 are consistent with the observation that activated Ras has pro-apoptotic activity in Rat1mycER cells through its stimulation of ERK MAP kinases (13). These results suggest that Rac is distinct in its ability to promote cell survival in the presence of an apoptotic stimulus.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 3.   Apoptosis in cells stably expressing activated or dominant-inhibitory small G proteins. A, Rat1mycER cells stably expressing RacV12, Cdc42V12, RasD12, or vector only (VO) were treated with or without 100 nM tamoxifen and with or without 1 µM insulin. After 20 h of treatment at 37 °C, at least 300 cells were counted for each treatment and the percentage of apoptotic cells was calculated. The expression of the small G protein in each cell line is indicated by the Western blots above each graph. B, Rat1mycER cells (circles) or Rat1mycER cells expressing RacV12 (squares) were treated with (closed symbols) or without (open symbols) 100 nM tamoxifen to induce apoptosis. The cells were observed for 18 h using time-lapse video microscopy. The percentage of apoptotic cells was calculated every 2 h. C, Rat1mycER cells stably expressing Cdc42N17, or RasN17, were treated as described for A, and the percentage of apoptotic cells was calculated. The results are presented as the mean ± S.D. of three or more independent experiments. D, Rat1mycER cells expressing Cdc42N17 were treated with 100 nM tamoxifen (closed squares) or 100 nM tamoxifen and 1 µM insulin (open squares). The cells were observed, and the percentage of apoptotic cells was determined as described in B. Statistical significance was determined by a Student's t test; p < 0.01 for a-e, (A) and a-d (C) in comparison with control cells treated with tamoxifen alone. Asterisks indicate the statistical difference (p < 0.01) in the level of apoptosis between Rat1mycER cells treated with tamoxifen and tamoxifen-treated Rat1mycER cells expressing RacV12 (B) or in the level of apoptosis of Rat1mycER cells stably expressing Cdc42N17 treated with tamoxifen or tamoxifen and insulin (D).

The expression of dominant-inhibitory Cdc42N17 or RasN17 in Rat1mycER cells had no effect on tamoxifen-induced apoptosis and did not alter insulin's ability to inhibit tamoxifen-induced apoptosis (Figs. 3, C and D). We were unable to create cell lines stably expressing RacN17. As a second approach toward determining whether Rac contributed to survival signaling, plasmids encoding dominant-inhibitory RacN17 were microinjected into Rat1mycER fibroblasts expressing the CSF1R/IRDelta 960 (Fig. 4). Apoptosis in untreated cells was 11.5%, whereas tamoxifen treatment alone elevated the level of apoptosis to 36.3%. Tamoxifen treatment in combination with insulin or CSF-1 significantly reduced the amount of apoptosis to 18.9% and 20%, respectively. Untreated cells injected with an expression plasmid encoding RacN17 showed a level of apoptosis comparable with untreated cells or cells treated with tamoxifen plus insulin or CSF-1. Tamoxifen increased apoptosis in cells injected with plasmids encoding RacN17 to the same extent as control injected cells treated with tamoxifen, which demonstrated that dominant-inhibitory RacN17 has no protective effect on the cells. However, the anti-apoptotic effects of insulin and CSF-1 were lost in cells injected with RacN17 (Fig. 4).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 4.   Apoptosis in cells microinjected with RacN17. Rat1mycER cells expressing the CSF1R/IRDelta 960 were left untreated or microinjected with DNA encoding GFP (20 ng/µl) or GFP plus RacN17 (50 ng/µl) DNA. Five hours after injection, the fluorescent cells were counted, and the cells were treated with 100 nM tamoxifen, 1 µM insulin, or 10 nM CSF-1 as indicated. After incubation at 37 °C for 20 h the number of fluorescent cells remaining was determined and the percentage of apoptosis was calculated. The results are presented as the mean ± S.D. of three or more independent experiments. Statistical significance was determined by a Student's t test; a-d, p < 0.01 in comparison to control cells treated with tamoxifen alone.

The data demonstrate that receptor signaling to Rac is independent of the phosphorylation of IRS-1 and Shc, as a deletion in the juxtamembrane domain prevented the chimeric CSF1R/IR (6) and the intact insulin receptor (1, 30-32) from interacting with and phosphorylating these important signaling intermediates. Ras (33), Cdc42, (34) and PI 3-kinase (35) are considered to be activators of Rac. However, CSF1R/IR activation of Ras-regulated pathways is inhibited by the Delta 960 mutation (6), and neither dominant-inhibitory RasN17 nor Cdc42N17 blocked the ability of the CSF1R/IRDelta 960 to induce membrane ruffling (data not shown) or survival (Fig. 3). PI 3-kinase associated with IRS-1 is activated by the CSF1R/IR, but is not activated by the CSF1R/IRDelta 960 (6). These previous observations and the data presented here suggest the existence of a novel intracellular signaling pathway used by the insulin receptor kinase to induce membrane ruffling and to transmit intracellular signals promoting cell survival.

The PI 3-kinase-dependent activation of Akt and the subsequent phosphorylation of the pro-apoptotic protein Bad (12), caspase 9 (36), and the forkhead transcription factor FKHRL1 (37) have been identified previously as elements of a growth factor-mediated survival mechanism. The data presented here suggest that growth factors with the ability to activate the small GTPase Rac may stimulate additional pathways to inhibit apoptosis. Rac is an effector of multiple signaling pathways (38), any one of which may contribute to the inhibition of apoptosis. Activated Rac promotes survival in BaF3 cells in a manner that is inhibited by the p38 kinase inhibitor SB203580 (39). Rac can also activate the NADPH burst oxidase (40), which, in turn, can activate the anti-apoptotic transcription factor NFkappa beta (41, 42). This latter possibility suggests an additional survival pathway dependent on new gene transcription. In this regard, it is interesting to note that a novel anti-apoptotic signaling pathway was recently described for the IGF I receptor that is sensitive to the RNA polymerase II inhibitor alpha -amanitin (19). The identification of Rac as a transitional element in these biological events should provide a valuable point of reference for the identification and ordering of additional signaling intermediates that regulate cytoskeletal changes and survival by the insulin receptor kinase.

    ACKNOWLEDGEMENTS

We express our appreciation to A. Hall, D. Bar-Sagi, and G. Evan for reagents; to Genetics Institute (Cambridge, MA.) for the invaluable gift of recombinant human CSF-1; and to R. Cotter for preliminary experiments that led to these studies.

    FOOTNOTES

* This work was supported in part by Grants RPG-96-134-03-TBE from the American Cancer Society, DK52809 from the National Institutes of Health, 99-24 from the Nebraska Department of Health and Human Services, and P30 CA36727 from the National Cancer Institute to the Eppley Institute.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Supported by Training Grant CA09476 from the National Cancer Institute.

** To whom correspondence should be addressed: Eppley Cancer Institute, University of Nebraska Medical Center, 986805 Nebraska Medical Center, Omaha, NE 68198-6805. Tel.: 402-559-8290; Fax: 402-559-4651; E-mail: rlewis@unmc.edu.

    ABBREVIATIONS

The abbreviations used are: IGF I, insulin-like growth factor I; IRS, insulin receptor substrate, CSF-1, colony-stimulating factor-1; CSF1R/IR, colony-stimulating factor-1 receptor/insulin receptor chimera; CSF1R/IRDelta 960, receptor chimera containing a 12-amino acid deletion in the cytoplasmic juxtamembrane region; PI, phosphatidylinositol, GFP, green fluorescent protein, MAP, mitogen-activated protein; ERK, extracellular regulated kinase; TRITC, tetramethylrhodamine B isothiocyanate.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. White, M. F., Livingston, J. N., Backer, J. M., Lauris, V., Ullrich, A., and Kahn, C. R. (1988) Cell 54, 641-649[CrossRef][Medline] [Order article via Infotrieve]
2. Maegawa, H., McClain, D. A., Friedenberg, G., Olefsky, J. M., Napier, M., Lipari, T., Dull, T. J., Lee, J., and Ullrich, A. (1988) J. Biol. Chem. 263, 8912-8917[Abstract/Free Full Text]
3. Theis, R. S., Ullrich, A., and McClain, D. A. (1989) J. Biol. Chem. 264, 12820-12825[Abstract/Free Full Text]
4. Yonezawa, K., Ando, A., Kaburagi, Y., Yamamoto-Honda, R., Kitamura, T., Hara, K., Nakafuku, M., Okabayashi, Y., Kadowaki, T., Kaziro, Y., and Kasuga, M. (1994) J. Biol. Chem. 269, 4634-4640[Abstract/Free Full Text]
5. Chaika, O. V., Chaika, N., Volle, D. J., Wilden, P. A., Pirrucello, S. J., and Lewis, R. E. (1997) J. Biol. Chem. 272, 11968-11974[Abstract/Free Full Text]
6. Boehm, J. E., Chaika, O. V., and Lewis, R. E. (1998) J. Biol. Chem. 273, 7169-7176[Abstract/Free Full Text]
7. Chaika, O. V., Chaika, N., Volle, D. J., Hayashi, H., Ebina, Y., Wang, L. M., Pierce, J. H., and Lewis, R. E. (1999) J. Biol. Chem. 274, 12075-12080[Abstract/Free Full Text]
8. Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I. (1994) EMBO J. 13, 3286-3295[Medline] [Order article via Infotrieve]
9. Baserga, R., Hongo, A., Rubini, M., Prisco, M., and Valentinis, B. (1997) Biochim. Biophys. Acta Rev. Cancer 1332, F105-F126[Medline] [Order article via Infotrieve]
10. Hossenlopp, P., Seurin, D., Segovia-Quinson, B., Hardouin, S., and Binoux, M. (1986) Anal. Biochem. 154, 138-143[CrossRef][Medline] [Order article via Infotrieve]
11. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R. J., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. (1997) Science 275, 661-665[Abstract/Free Full Text]
12. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H. A., Gotoh, Y., and Greenberg, M. E. (1997) Cell 91, 231-241[CrossRef][Medline] [Order article via Infotrieve]
13. Kauffman-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., and Evan, G. (1997) Nature 385, 544-548[CrossRef][Medline] [Order article via Infotrieve]
14. Shoelson, S. E., Chatterjee, S., Chaudhuri, M., and White, M. F. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2027-2031[Abstract/Free Full Text]
15. Backer, J. M., Myers, M. G., Jr., Shoelson, S. E., Chin, D. J., Sun, X.-J., Miralpeix, M., Hu, P., Margolis, B., Skolnik, E. Y., Schlessinger, J., and White, M. F. (1992) EMBO J. 11, 3469-3479[Medline] [Order article via Infotrieve]
16. Myers, M. G., Jr., Backer, J. M., Sun, X. J., Shoelson, S., Hu, P., Schlessinger, J., Yoakim, M., Schaffhausen, B., and White, M. F. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10350-10354[Abstract/Free Full Text]
17. Pear, W. S., Nolan, G. P, Scott, M. L., and Baltimore, D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8392-8396[Abstract/Free Full Text]
18. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. (1992) Cell 69, 119-128[CrossRef][Medline] [Order article via Infotrieve]
19. Kulik, G., and Weber, M. J. (1998) Mol. Cell. Biol. 18, 6711-6718[Abstract/Free Full Text]
20. Joneson, T., Fulton, J. A., Volle, D. J., Chaika, O. V., Bar-Sagi, D., and Lewis, R. E. (1998) J. Biol. Chem. 273, 7743-7748[Abstract/Free Full Text]
21. Bockus, B. J., and Stiles, C. D. (1984) Exp. Cell Res. 153, 186-197[CrossRef][Medline] [Order article via Infotrieve]
22. Kotani, K., Yonezawa, K., Hara, K., Ueda, H., Kitamura, Y., Sakaue, H., Ando, A., Chavanieu, A., Calas, B., Grigorescu, F., Nishiyama, M., Waterfield, M. D., and Kasuga, M. (1994) EMBO J. 13, 2313-2321[Medline] [Order article via Infotrieve]
23. Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., and Hall, A. (1992) Cell 70, 401-410[CrossRef][Medline] [Order article via Infotrieve]
24. Han, J. W., Luby-Phelps, K., Das, B., Shu, X. D., Xia, Y., Mosteller, R. D., Krishna, U. M., Falck, J. R., White, M. A., and Broek, D. (1998) Science 279, 558-560[Abstract/Free Full Text]
25. Nimnual, A. S., Yatsula, B. A., and Bar-Sagi, D. (1998) Science 279, 560-563[Abstract/Free Full Text]
26. Franke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., and Tsichlis, P. N. (1995) Cell 81, 727-736[CrossRef][Medline] [Order article via Infotrieve]
27. Klippel, A., Kavanaugh, W. M., Pot, D., and Williams, L. T. (1997) Mol. Cell. Biol. 17, 338-344[Abstract]
28. Franke, T. F., Kaplan, D. R., Cantley, L. C., and Toker, A. (1997) Science 275, 665-668[Abstract/Free Full Text]
29. Frech, M., Andjelkovic, M., Ingley, E., Reddy, K. K., Falck, J. R., and Hemmings, B. A. (1997) J. Biol. Chem. 272, 8474-8481[Abstract/Free Full Text]
30. Backer, J. M., Schroeder, G. G., Cahill, D. A., Ullrich, A., Siddle, K., and White, M. F. (1991) Biochemistry 30, 6366-6372[CrossRef][Medline] [Order article via Infotrieve]
31. Gustafson, T. A., He, W., Craparo, A., Schaub, C. D., and O'Neill, T. J. (1995) Mol. Cell. Biol. 15, 2500-2508[Abstract]
32. O'Neill, T. J., Craparo, A., and Gustafson, T. A. (1994) Mol. Cell. Biol. 14, 6433-6442[Abstract/Free Full Text]
33. Joneson, T., White, M. A., Wigler, M. H., and Bar-Sagi, D. (1996) Science 271, 810-812[Abstract]
34. Nobes, C. D., and Hall, A. (1995) Cell 81, 53-62[CrossRef][Medline] [Order article via Infotrieve]
35. Rodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., and Downward, J. (1997) Cell 89, 457-467[CrossRef][Medline] [Order article via Infotrieve]
36. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., and Reed, J. C. (1998) Science 282, 1318-1321[Abstract/Free Full Text]
37. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. (1999) Cell 96, 857-868[CrossRef][Medline] [Order article via Infotrieve]
38. Tapon, N., and Hall, A. (1997) Curr. Opin. Cell Biol. 9, 86-92[CrossRef][Medline] [Order article via Infotrieve]
39. Nishida, K., Kaziro, Y., and Satoh, T. (1999) Oncogene 18, 407-415[CrossRef][Medline] [Order article via Infotrieve]
40. Abo, A., Pick, E., Hall, A., Totty, N., Teahan, C. G., and Segal, A. W. (1991) Nature 353, 668-670[CrossRef][Medline] [Order article via Infotrieve]
41. Perona, R., Montaner, S., Saniger, L., Sanchez-Perez, I., Bravo, R., and Lacal, J. C. (1997) Genes Dev. 11, 463-475[Abstract/Free Full Text]
42. Sulciner, D. J., Irani, K., Yu, Z. X., Ferrans, V. J., Goldschmidt-Clermont, P., and Finkel, T. (1997) Mol. Cell. Biol. 16, 7115-7121[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
IOVSHome page
Q.-L. Fu, B. Hu, W. Wu, R. B. Pepinsky, S. Mi, and K.-F. So
Blocking LINGO-1 Function Promotes Retinal Ganglion Cell Survival Following Ocular Hypertension and Optic Nerve Transection
Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 975 - 985.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
B. Zhang, Y. Zhang, and E. Shacter
Caspase 3-Mediated Inactivation of Rac GTPases Promotes Drug-Induced Apoptosis in Human Lymphoma Cells
Mol. Cell. Biol., August 15, 2003; 23(16): 5716 - 5725.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Otsuki, M. Tanaka, T. Kamo, C. Kitanaka, Y. Kuchino, and H. Sugimura
Guanine Nucleotide Exchange Factor, Tiam1, Directly Binds to c-Myc and Interferes with c-Myc-mediated Apoptosis in Rat-1 Fibroblasts
J. Biol. Chem., February 7, 2003; 278(7): 5132 - 5140.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. Eichhorn, A. G. Kayali, L. Resor, D. A. Austin, D. W. Rose, and N. J. G. Webster
PLC-{gamma}1 Enzyme Activity Is Required for Insulin-Induced DNA Synthesis
Endocrinology, February 1, 2002; 143(2): 655 - 664.
[Abstract] [Full Text] [PDF]


Home page
Cell Growth Differ.Home page
H. Qi, P. Juo, J. Masuda-Robens, M. J. Caloca, H. Zhou, N. Stone, M. G. Kazanietz, and M. M. Chou
Caspase-mediated Cleavage of the TIAM1 Guanine Nucleotide Exchange Factor during Apoptosis
Cell Growth Differ., December 1, 2001; 12(12): 603 - 611.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. A. Linseman, T. Laessig, M. K. Meintzer, M. McClure, H. Barth, K. Aktories, and K. A. Heidenreich
An Essential Role for Rac/Cdc42 GTPases in Cerebellar Granule Neuron Survival
J. Biol. Chem., October 12, 2001; 276(42): 39123 - 39131.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
A. Clerk, F. H. Pham, S. J. Fuller, E. Sahai, K. Aktories, R. Marais, C. Marshall, and P. H. Sugden
Regulation of Mitogen-Activated Protein Kinases in Cardiac Myocytes through the Small G Protein Rac1
Mol. Cell. Biol., February 15, 2001; 21(4): 1173 - 1184.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
S. J. Coniglio, T.-S. Jou, and M. Symons
Rac1 Protects Epithelial Cells against Anoikis
J. Biol. Chem., July 20, 2001; 276(30): 28113 - 28120.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Caruso, M. A. Maitan, G. Bifulco, C. Miele, G. Vigliotta, F. Oriente, P. Formisano, and F. Beguinot
Activation and Mitochondrial Translocation of Protein Kinase Cdelta Are Necessary for Insulin Stimulation of Pyruvate Dehydrogenase Complex Activity in Muscle and Liver Cells
J. Biol. Chem., November 21, 2001; 276(48): 45088 - 45097.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boehm, J. E.
Right arrow Articles by Lewis, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boehm, J. E.
Right arrow Articles by Lewis, R. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.